Ying E Fu

US Patent:

7572783, Aug 11, 2009

Filed:

Aug 12, 2005

Appl. No.:

11/203562

Inventors:

Xi Chen - Palo Alto CA, US
Xiaoqi Chen - San Mateo CA, US
Richard Victor Connors - Pacifica CA, US
Kang Dai - Albany CA, US
Ying Fu - Menlo Park CA, US
Juan C. Jaen - Burlingame CA, US
Yong-Jae Kim - Foster City CA, US
Leping Li - Burlingame CA, US
Mike E. Lizarzaburu - San Diego CA, US
Jeffrey T. Mihalic - San Francisco CA, US
Stephen J. Shuttleworth - Bourne End, GB

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/4709
A61K 31/553
C07D 217/02
C07D 267/02

US Classification:

51421109, 514221, 514307, 514412, 540490, 540500, 540504, 546140, 548469

Abstract:

The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.

US Patent:

20040142956, Jul 22, 2004

Filed:

Sep 23, 2003

Appl. No.:

10/669606

Inventors:

Xiaoqi Chen - San Mateo CA, US
Kang Dai - Albany CA, US
Pingchen Fan - Fremont CA, US
Ying Fu - Menlo Park CA, US
Leping Li - Burlingame CA, US
Jeffrey Mihalic - San Francisco CA, US

International Classification:

A61K031/4747

US Classification:

514/278000, 546/017000, 546/018000

Abstract:

Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and/or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.

US Patent:

20060134619, Jun 22, 2006

Filed:

Nov 26, 2003

Appl. No.:

10/536735

Inventors:

Louis Ptacek - San Francisco CA, US
Christopher Jones - Salt Lake City UT, US
Ying Fu - San Francisco CA, US

International Classification:

C12Q 1/68
C07H 21/04
C12P 21/06
C12N 9/12

US Classification:

435006000, 435069100, 435194000, 435320100, 435325000, 536023200

Abstract:

Genetic variants of the casein kinase I delta and casein kinase I epsilon genes are disclosed. Herein, two novel mutant casein kinase I delta genes and a novel mutant casein kinase I epsilon gene are disclosed. The protein products of the mutant casein kinase I delta gene and the mutant casein kinase I epsilon gene are also disclosed. The nucleic acid sequences of the invention lead to familial advanced sleep phase syndrome.

US Patent:

20070078152, Apr 5, 2007

Filed:

Dec 16, 2005

Appl. No.:

11/303456

Inventors:

Xiaoqi Chen - San Mateo CA, US
Kang Dai - Albany CA, US
Pingchen Fan - Fremont CA, US
Ying Fu - Menlo Park CA, US
Leping Li - Burlingame CA, US
Jeffrey Mihalic - San Francisco CA, US

International Classification:

A61K 31/4747
C07D 471/10

US Classification:

514278000, 546015000, 546016000

Abstract:

Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and/or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.